新视野:管理骨质疏松症的人工智能工具
本文综述了人工智能工具在骨质疏松症管理中的应用进展。骨质疏松症以低骨量和微结构退化为特征,骨折常发生于非骨质疏松的骨密度值,且全球主要指南在治疗时机、对象和药物选择上共识有限。人工智能算法的性能至少与医师专家相当甚至更优,但研究结果需谨慎解读,存在参考标准不当或变量选择临床价值低等局限,亟需高质量临床研究及国际共识的最佳实践框架。
要点
- 骨质疏松症管理面临骨折常发生于非骨质疏松骨密度值及诊断不足的挑战。
- 全球主要指南在治疗时机、对象和药物选择上共识有限。
- 人工智能算法性能至少与医师专家相当甚至更优,但结果需谨慎解读。
核心结论
- 人工智能算法在骨质疏松症管理中的性能至少与医师专家相当甚至更优,但研究结果应始终谨慎解读。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 许多新开发的人工智能算法性能至少与医师专家相当甚至更优。
- 研究结果常存在参考标准不当或选择临床实践价值低或无价值的变量等局限。
关键数值与推荐
- 原文未报告具体标准或数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究结果常存在参考标准不当或选择临床实践价值低或无价值的变量等局限。
- 该领域需要高质量临床研究,可通过建立考虑所有相关利益方的国际共识「最佳实践框架」来实现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration leading to increased bone fragility and fracture risk. Typically, osteoporotic fractures occur at the spine, hip, distal forearm, and proximal humerus, but other skeletal sites may be affected as well. One of the major challenges in the management of osteoporosis lies in the fact that although the operational diagnosis is based on bone mineral density (BMD) as measured by dual x-ray absorptiometry, the majority of fractures occur at nonosteoporotic BMD values. Furthermore, osteoporosis often remains undiagnosed regardless of the low severity of the underlying trauma. Also, there is only weak consensus among the major guidelines worldwide, when to treat, whom to treat, and which drug to use. Against this background, increasing efforts have been undertaken in the past few years by artificial intelligence (AI) developers to support and improve the management of this disease. The performance of many of these newly developed AI algorithms have been shown to be at least comparable to that of physician experts, or even superior. However, even if study results appear promising at a first glance, they should always be interpreted with caution. Use of inadequate reference standards or selection of variables that are of little or no value in clinical practice are limitations not infrequently found. Consequently, there is a clear need for high-quality clinical research in this field of AI. This could, eg, be achieved by establishing an internationally consented "best practice framework" that considers all relevant stakeholders.
引用
- Dimai HP. New Horizons: Artificial Intelligence Tools for Managing Osteoporosis. J Clin Endocrinol Metab. 2023. PMID: 36477337. doi:10.1210/clinem/dgac702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。